The Solupore, non-viral delivery platform, engineered by Avectas, enables the next generation of cell therapies, expanding the possibilities for complex editing workflows in cell therapy manufacturing. Solupore can facilitate sequential delivery and multiplex editing enabling applications in autologous CAR-T cell therapies and in the reprogramming of blood cells to iPS cells.
Partnerships are essential to ensure better patient outcomes, and we are actively seeking to engage with companies and researchers who are developing these life-saving gene-modified cell therapy products. If you would like to learn more about working with Avectas and our technology, get in touch with us.
Avectas' Solupore® platform offers a cell engineering solution for next-generation cell therapies. Partnerships are essential to ensure better patient outcomes, and we are actively seeking to engage with companies and researchers who are developing these life-saving gene-modified cell therapy products. If you would like to learn more about working with Avectas, please get in touch with us.
Contact Us
Increased functional potency of multi-edited CAR-T cells manufactured by a non-viraltransfection system.
